Yemen
Tuberculosis profile
Population  2013 24 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.99 (0.47–1.7) 4.1 (1.9–6.9)
Mortality (HIV+TB only) 0.018 (<0.01–0.03) 0.07 (0.04–0.12)
Prevalence  (includes HIV+TB) 15 (5.8–27) 60 (24–112)
Incidence  (includes HIV+TB) 12 (10–13) 48 (42–54)
Incidence (HIV+TB only) 0.1 (0.041–0.12) 0.43 (0.17–0.49)
Case detection, all forms (%) 88 (79–100)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.5–3) 15 (8.1–22)
MDR-TB cases among notified pulmonary
TB cases
110 (31–190) 47 (26–69)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 2 995   274
Pulmonary, clinically diagnosed 3 283   0
Extrapulmonary 3 773   0
       
Total new and relapse 10 325    
Previously treated, excluding relapses 42    
Total cases notified 10 367    
Among 10 367 new and relapse cases:
1 082 (10%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 583 (19%) 56 (18%) 639
Laboratory-confirmed RR-/MDR-TB cases     19
Patients started on MDR-TB treatment     9
TB/HIV 2013 Number (%)
TB patients with known HIV status 788 (8)
HIV-positive TB patients 23 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 278  
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 88
Previously treated cases registered in 2012 43
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.8
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 6.3
% Funded domestically 18%
% Funded internationally 60%
% Unfunded 22%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-29 Data: www.who.int/tb/data